Patent Issued for Engineered producer cell lines and methods of making and using the same (USPTO 12018288).

Ultragenyx Pharmaceutical Inc. has been issued a patent for engineered producer cell lines and methods of making and using them. The patent addresses the need for improved recombinant adeno-associated virus (rAAV) titers for gene therapy applications. The invention provides rAAV packaging and/or producer cell lines that can produce higher titers of rAAV compared to control parental cells. The patent also describes methods of generating these engineered cell lines and their potential applications in producing rAAV for gene therapy. [Extracted from the article]